1. Home
  2. BNED vs FHTX Comparison

BNED vs FHTX Comparison

Compare BNED & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnes & Noble Education Inc

BNED

Barnes & Noble Education Inc

HOLD

Current Price

$9.12

Market Cap

307.2M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.88

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNED
FHTX
Founded
1965
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
307.2M
360.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BNED
FHTX
Price
$9.12
$5.88
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$11.43
AVG Volume (30 Days)
376.7K
195.7K
Earning Date
01-20-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$1,677,191,000.00
$24,518,000.00
Revenue This Year
N/A
$40.91
Revenue Next Year
N/A
$11.87
P/E Ratio
$189.19
N/A
Revenue Growth
7.64
N/A
52 Week Low
$5.90
$2.95
52 Week High
$12.21
$6.95

Technical Indicators

Market Signals
Indicator
BNED
FHTX
Relative Strength Index (RSI) 54.11 55.22
Support Level $8.65 $5.55
Resistance Level $9.70 $6.29
Average True Range (ATR) 0.45 0.48
MACD 0.04 -0.03
Stochastic Oscillator 66.28 47.19

Price Performance

Historical Comparison
BNED
FHTX

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: